The University Hospital Geelong is an Australian public hospital located in Ryrie Street, Geelong, Victoria. The hospital is part of Barwon Health, Victoria's largest regional health care provider, which has 21 sites.

During the past decade, Barwon Health conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 18 clinical trials were completed, i.e. on average, 48.6% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 13 clinical trials were completed. i.e. 86.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Barwon Health" #1 sponsor was "Eli Lilly and Company" with 8 trials, followed by "Australian and New Zealand Intensive Care Research Centre" with 7 trials sponsored, "Pfizer" with 6 trials sponsored, "Barwon Health" with 5 trials sponsored and "Australasian Gastro-Intestinal Trials Group" with 5 trials sponsored. Other sponsors include 40 different institutions and companies that sponsored additional 44 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Barwon Health" #1 collaborator was "National Health and Medical Research Council, Australia" with 8 trials as a collaborator, "Baxter Healthcare Corporation" with 3 trials as a collaborator, "Medical Research Institute of New Zealand" with 3 trials as a collaborator, "ANZICS Clinical Trials Group" with 2 trials as a collaborator and "Australian and New Zealand Intensive Care Society Clinical Trials Group" with 2 trials as a collaborator. Other collaborators include 66 different institutions and companies that were collaborators in the rest 70 trials.

According to Clinical.Site data, the most researched conditions in "Barwon Health" are "Atrial Fibrillation" (3 trials), "Breast Cancer" (3 trials), "Critical Illness" (3 trials), "Type 2 Diabetes" (3 trials) and "Type 2 Diabetes Mellitus" (3 trials). Many other conditions were trialed in "Barwon Health" in a lesser frequency.

Most popular intervention types in "Barwon Health" are "Drug" (50 trials), "Other" (12 trials), "Biological" (11 trials), "Procedure" (6 trials) and "Behavioral" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Tirzepatide" (5 trials), "Carboplatin" (3 trials), "Rituximab" (3 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Barwon Health" are 66 trials for "All" genders, 4 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Barwon Health". undefined are not yet recruiting, 15 are recruiting, 9 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 31 completed trials in Barwon Health, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Barwon Health, 9 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 42 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 6 trials that are defined as “Not Applicable".

Barwon Health has several departments that took part in Clinical trials: "Andrew Love Cancer Care Centre, Geelong Hospital" - 21 trials